Clinical Trials Sponsored by West German Study Group

Total 122 results

West German Study Group
AGO Germany

Completed

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Breast Cancer

Germany
West German Study Group

Active, not recruiting

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer (ADAPT)

Breast Cancer

Germany
West German Study Group

Active, not recruiting

ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer (ADAPT)

Breast Cancer

Germany
West German Study Group
GlaxoSmithKline

Terminated

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Carcinoma, Ductal, Breast

Germany
West German Study Group
Agendia

Completed

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe) (PRIMe)

Breast Cancer

Switzerland, Austria, Germany
West German Study Group
AstraZeneca

Not yet recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)

HER2-positive Early Breast Cancer

Germany
West German Study Group
Agendia

Recruiting

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS (PROOFS)

Female Breast Cancer

Germany
West German Study Group
Celgene

Active, not recruiting

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer (ADAPT)

Breast Cancer

Germany
West German Study Group
Sanofi; Amgen

Completed

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer (planB)

Primary Breast Cancer | Her2 Non-overexpressing

Germany
West German Study Group
Roche Pharma AG

Active, not recruiting

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. (ADAPT; T-DM1)

Breast Cancer

Germany
West German Study Group
Teva Pharmaceuticals USA

Active, not recruiting

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

Early Primary Breast Cancer

Germany
West German Study Group
Roche Pharma AG

Recruiting

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (ADAPT)

Breast Cancer

Germany
West German Study Group
Sanofi; Roche Pharma AG

Terminated

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

Breast Cancer

Germany
German CLL Study Group

Recruiting

Registry of the German CLL Study Group (CLL-Registry)

CLL | Leukemia, Prolymphocytic, T-Cell | SLL | Leukemia, Prolymphocytic, B-Cell | HCL | T-LGL Leukemia | Richter´s Transformation | NK-LGL Leukemia

Germany
German CLL Study Group

Completed

Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

France, Germany, Austria
German CLL Study Group

Completed

Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia

Anemia | Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia

Canada, Germany
German CLL Study Group

Terminated

Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia

T-Cell Large Granular Lymphocytic Leukemia

Germany
German CLL Study Group

Terminated

Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
German CLL Study Group

Terminated

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

Prolymphocytic Leukemia

Germany
German CLL Study Group

Active, not recruiting

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG)

Chronic Lymphoid Leukemia

Germany
German CLL Study Group

Active, not recruiting

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail)

Chronic Lymphoid Leukemia

Austria, Germany
German CLL Study Group

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL (CLL2-BAAG)

Chronic Lymphoid Leukemia

Germany
German CLL Study Group

Completed

Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Active, not recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

Richter Transformation

Denmark, Germany, Austria
German CLL Study Group

Completed

Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group

Completed

Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Prolymphocytic Leukemia

Germany, Austria
German CLL Study Group

Completed

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
West German Study Group
Novartis; Genomic Health®, Inc.

Recruiting

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle)

Breast Cancer Female

Germany
German Breast Group
AGO Study Group

Completed

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

Breast Cancer

Germany
German Breast Group
AGO Study Group

Completed

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Breast Cancer

Germany
West German Study Group
Merck Sharp & Dohme LLC; Gilead Sciences

Not yet recruiting

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (ADAPT-TN-III)

Triple Negative Breast Cancer
German CLL Study Group
AstraZeneca

Recruiting

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group
Celgene

Completed

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Chronic Lymphocytic Leukemia

Germany
German Parkinson Study Group (GPS)

Completed

STN-Stimulation Versus Best Medical Treatment in Advanced PD

Parkinson's Disease

Germany
West German Study Group
Merck Sharp & Dohme LLC; NanoString Technologies, Inc.

Completed

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) (Keyriched-1)

Breast Cancer

Germany
Gilead Sciences
German CLL Study Group

Completed

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Gilead Sciences
German CLL Study Group

Completed

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
German Low Grade Lymphoma Study Group

Terminated

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma (R-GO)

Indolent Lymphoma

Germany
West German Study Group
Eli Lilly and Company; Genomic Health®, Inc.

Recruiting

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC (ADAPTlate)

Breast Cancer Female

Germany
German CLL Study Group
Janssen-Cilag Ltd.

Completed

Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression (CLL12)

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group
University of Cologne

Completed

Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
Hoffmann-La Roche
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia (CLL-8)

Leukemia

France, Australia, Belgium, Italy, Germany, Israel, New Zealand, Czech Republic, Spain, Austria, Denmark
German CLL Study Group
Hoffmann-La Roche

Terminated

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation (CLLTX1)

Chronic Lymphocytic Leukemia | Richter's Transformation

Germany
Munich Municipal Hospital
German CLL Study Group

Unknown

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Chronic Lymphocytic Leucemia

Germany

3

Subscribe